Search Bar & Filters
Found 56 Actively Recruiting clinical trials
Actively Recruiting
This observational study focuses on children under 18 years of age with tracheostomies who are followed at the Long-Term Intensive Care Unit LIVA at Karolinska University Hospital in Sweden. It aims to determine how often tracheostomy-related airway complications are asymptomatic or linked to symptoms detected through surveillance airway endoscopy. Additionally, the study evaluates how accurately caregivers and pediatricians can identify symptoms related to serious airway complications. Children scheduled for regular surveillance airway endoscopy under anesthesia as part of their follow-up at LIVA will be included. Upon admission, caregivers complete a questionnaire about possible symptoms of airway complications. The child then undergoes a physical exam and medical history review by a pediatrician following a set protocol. An ENT surgeon, unaware of the questionnaire and pediatrician exam results, performs the airway endoscopy to identify complications. During the study, researchers will compare caregiver and pediatrician reports with findings from airway endoscopy to assess symptom reliability. The main measurements include the proportion of patients with serious tracheostomy airway complications who show no symptoms before endoscopy. The study spans two years, with ongoing surveillance and the collection of data on symptoms and complications. Ethical approval has been obtained to conduct this research.
Actively Recruiting
Researchers are evaluating the combination of CGT9486 and sunitinib compared to sunitinib alone in patients with locally advanced, unresectable, or metastatic Gastrointestinal Stromal Tumors GIST. This Phase 3, open-label international trial involves multiple parts, including dose confirmation, drug interaction assessments, and efficacy comparisons. The study also includes substudies focusing on drug-drug interaction potential and first-line treatment in patients with specific genetic mutations KIT exon 9. Approximately 482 patients will participate across these parts.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating a new imaging agent called 18FACI-15916 to detect and measure the accumulation of abnormal alpha-synuclein protein in the brain. This protein is involved in diseases such as Parkinsons disease, Lewy body dementia, and Multiple System Atrophy, collectively called alpha-synucleinopathies. The study includes both healthy volunteers and people suspected to have alpha-synuclein pathology to assess safety and imaging reliability. Participants receive an intravenous injection of the radioactive tracer 18FACI-15916 and undergo positron emission tomography PET scans to visualize alpha-synuclein deposits. The study has four parts involving different groups, including healthy volunteers and patients with Parkinsons disease, Multiple System Atrophy, or Dementia with Lewy Bodies. Some participants may have a second PET scan to test reproducibility. A subset will also undergo whole-body PET-CT scans to evaluate the tracers distribution and radiation dose. Participants visit the clinic for screening, including physical and neurological exams, questionnaires, blood and urine tests, ECG, and in some cases additional imaging with MRI or PET using a licensed tracer. After receiving the tracer and PET scan, blood samples and optional spinal fluid samples are collected. Safety follow-up phone calls occur one week after scans to monitor side effects. The study duration ranges from up to 10 weeks for most participants to up to 14 weeks for those with repeat scans.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how different doses of a study medicine called Inno8 work in the bodies of people with haemophilia A. The purpose is to see if Inno8 is safe for use in this condition. This is a phase 1 treatment study sponsored by Novo Nordisk AS, lasting about 11 weeks, involving adult males with haemophilia A. Participants will receive oral doses of the study drug NNC0442-0344 A across three experimental cohorts. The dosing will be monitored closely throughout the study period. The study is designed as a single-group, non-randomized trial without blinding. During the study, participants will be evaluated for side effects and blood markers related to coagulation, such as D-dimer, prothrombin fragments, fibrinogen, and platelets. Researchers will also measure drug concentration levels and immune response indicators from the first dose through to the end of follow-up at Day 46. Safety assessments will be ongoing to monitor adverse events during the treatment and follow-up period.
Actively Recruiting
Researchers are studying participants with active systemic lupus erythematosus SLE, including those with lupus nephritis, who have not responded adequately to glucocorticoids and at least two immunosuppressant therapies. The aim is to characterize the effectiveness and safety of current standard of care treatments for this condition. This observational study focuses on understanding how these treatments work in real-world settings for patients with active disease. Participants receive treatments based on the current standard of care according to product guidelines, including biologic therapies among other immunosuppressants. The study specifically includes those with active disease confirmed by clinical assessments and positive autoantibodies. Participants with lupus nephritis must have had a recent renal biopsy showing specific active kidney involvement. Treatment and observation continue over several years to evaluate long-term outcomes. During the study, participants undergo evaluations at regular intervals up to 60 months. Researchers assess disease remission, kidney function, disease activity scores, flare frequency, and patient-reported fatigue. Data collection involves clinical assessments, laboratory tests, and questionnaires to measure treatment response and safety. This long-term follow-up provides insight into how well patients maintain remission and respond to standard therapies over time.
Actively Recruiting
Researchers are studying Barretts Esophagus and early esophageal cancer to prepare for a larger future study. The study aims to collect tissue samples from the esophagus and blood to analyze genetic markers using new high-throughput methods. It also evaluates the quality of life and fear of cancer in patients with Barretts Esophagus, focusing on those referred for suspicion of high-grade dysplasia or early cancer. Participants will undergo two routine endoscopies during which standard biopsies and blood samples will be taken, along with additional samples specifically for the study. These include cells collected by brush cytology from the esophagus and up to ten tissue samples from the esophagus and stomach. The extra procedures extend the endoscopy by about 10-15 minutes. The study involves three contacts one screening visit and two sample collections during scheduled care. During the study, participants will complete questionnaires on quality of life and cancer worry at three different times using their mobile phones. Researchers will monitor the success of sample collection and genetic analysis over 6 to 24 months. Patient outcomes will be followed for up to five years through routine care visits without requiring extra visits. The study is sponsored by University Hospital, Antwerp.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of BMS-986482 alone and in combination with other therapies for people with advanced solid tumors that cannot be removed or have spread. This trial includes participants who have tried other treatments but are no longer benefiting or cannot use them. The study is sponsored by Bristol-Myers Squibb and includes both early and later phase evaluations to better understand this new therapy. Participants will receive BMS-986482 either by itself or combined with other drugs at specified doses on certain days. The study is randomized with multiple experimental groups to compare different treatment approaches. The goal is to assess how well these treatments work and how safe they are for participants with advanced cancers. During the study, participants will have regular assessments to monitor side effects, measure drug levels, and evaluate tumor response using standardized criteria. Researchers will track adverse events, serious side effects, and any reasons for stopping treatment up to four years after the last dose. This long-term monitoring helps understand both short- and long-term impacts of the treatments.
Actively Recruiting
Researchers are evaluating the efficacy and safety of ifinatamab deruxtecan I-DXd in adults with unresectable advanced or metastatic esophageal squamous cell carcinoma ESCC who have experienced disease progression after treatment with platinum-based chemotherapy and immune checkpoint inhibitors. This phase 3 clinical trial compares I-DXd to the investigators choice of chemotherapy in this patient group to assess overall survival benefits. Participants are randomly assigned to receive either intravenous infusions of I-DXd at 12 mgkg every 21 days or investigator-selected chemotherapy drugs such as docetaxel, paclitaxel, or irinotecan hydrochloride. Treatment cycles repeat every three weeks, continuing until disease progression or other study endpoints. The study will measure overall survival, progression-free survival, objective response rate, duration of response, disease control rate, quality of life changes, safety events, and pharmacokinetic parameters for up to approximately 54 months. Throughout the study, participants will undergo regular assessments including imaging scans to measure tumor lesions, quality of life questionnaires, and safety monitoring for adverse events. Blood samples will be collected to analyze drug levels and immune responses. The studys main outcome is overall survival from randomization to death from any cause. Participants health and response to treatment will be followed closely during and after treatment for up to 54 months, with continued monitoring of safety and effectiveness measures.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of Navlimetostat BMS-986504 alone or together with Izalontamab Brengitecan in adults with advanced or metastatic Non-small Cell Lung Cancer NSCLC who have a specific genetic change called homozygous MTAP deletion or MTAP loss. Participants have experienced disease progression despite prior treatments. This is a Phase 2 randomized, open-label trial sponsored by Bristol-Myers Squibb. Participants receive either Navlimetostat alone at one of two doses or in combination with Izalontamab Brengitecan at one of two doses. The study is designed with sequential treatment groups and evaluates these treatments after prior therapies have failed. Dosing details are specified for each drug on designated days, and the study includes assessments to confirm genetic status before treatment. Throughout the study, participants undergo evaluations for tumor response using RECIST criteria, safety monitoring for adverse events including serious reactions up to 28 days after treatment ends, and quality of life assessments related to NSCLC symptoms. The primary outcome focuses on objective tumor response, with follow-up extending up to three years after the last dose. Participants health and laboratory tests are closely monitored during and after treatment to assess safety and efficacy.
Actively Recruiting
Researchers are evaluating the effects of pitolisant on excessive daytime sleepiness EDS in patients aged 6 years and older with Prader-Willi syndrome. This Phase 3, randomized, double-blind, placebo-controlled global study aims to assess both the efficacy and safety of pitolisant. The study also investigates how pitolisant impacts irritable and disruptive behaviors, hyperphagia, and other behavioral issues such as social withdrawal, stereotypic behavior, hyperactivity, noncompliance, and inappropriate speech. The study includes an up to 45-day screening and baseline period followed by a double-blind treatment phase where participants are randomly assigned to receive either pitolisant tablets or matching placebo tablets once daily in the morning upon waking. This treatment period includes in-person visits on Days 29, 57, and 77. Afterward, participants may enter an optional open-label extension period receiving pitolisant, with visits on Days 113, 260, and 441. Follow-up visits occur 15 and 30 days after the last dose during both treatment periods. Participants will undergo various assessments including patient-reported measures of sleep-related impairment and caregiver and clinical impressions of sleepiness and behavior at baseline and the end of the double-blind phase. Behavioral scales like the Aberrant Behavior Checklist and Hyperphagia Questionnaire are used to evaluate changes. Safety is monitored by tracking adverse events throughout the study. The total duration of participation may extend beyond one year for those joining the extension period.
1-10 of 56
1